Those questions point to research that is still needed, Nieva says. This includes the role of deintensifying imaging and ...

Rusfertide was approved by the FDA 1 for adults with polycythemia who require phlebotomy, based on results from the phase 3 ...

Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with ...

The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Nieva also discussed the ROS1 fusion partner subgroup. Whether the partner was CD74 or another gene, the overall response ...

Andrew Kuykendall, MD, discusses where rusfertide (Mimrylo) may fit within the treatment paradigm for polycythemia vera and ...

Out-of-pocket costs drove abandonment: fill rates fell from ~80% at ≤$15 to ~30% at $500–$2000, and to 21.6% when >$2000 commercially. Prior authorization dominated rejection reasons (32.1% Medicare; ...

Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty. In this episode of The ...

Ubamatamab redirects T cells via CD3 engagement to MUC16-expressing tumor cells, leveraging uniformly high MUC16 expression in LGSOC and enabling responses without molecular preselection. At 800 mg ...

FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus ...

Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding ...